B형 및 C형 간염 진단약 시장 규모 : 검사 유형별, 최종 사용자별, 지역별 및 예측별

Hepatitis B and C Diagnostics Market Overview

The global hepatitis B and C diagnostics market, which encompasses diagnostic technologies and testing systems used for detection of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, is progressing moderately as demand increases across clinical laboratories, hospitals, and public health screening programs. Growth of the market is supported by expanding use of molecular diagnostic platforms, rising investments in infectious disease screening initiatives, and consistent testing demand from healthcare providers seeking early detection and monitoring of viral hepatitis infections.

Market outlook is further reinforced by modernization of laboratory infrastructure within emerging healthcare systems, heightened focus on early disease detection and preventive healthcare strategies, and increasing adoption of advanced diagnostic assays that deliver improved sensitivity, faster testing turnaround, and reliable infection screening across high risk populations.

Market size - VMR Analyst Corridor Approach

A revenue convergence corridor is emerging across recent global assessments instead of relying on a single-point estimate. Market value is consolidating around USD 3.89 Billion in 2025, while long-term projections are extending toward USD 5.92 Billion in 2033, reflecting mid- to high-single-digit growth momentum. A CAGR of 5.4% is being recorded over the forecast period (2027-2033), underscoring the market's structurally resilient growth trajectory.

Hepatitis B and C Diagnostics Market is estimated to grow at a CAGR of 5.4 % & reach US$ 5.92 Billion by the end of 2033

Global Hepatitis B and C Diagnostics Market Definition

The hepatitis B and C diagnostics market refers to the commercial ecosystem surrounding the development, production, distribution, and utilization of diagnostic tests and laboratory systems designed for detection of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. This market encompasses the supply of diagnostic technologies engineered for accurate viral detection, screening, and disease monitoring, with product offerings spanning serological assays, molecular diagnostic tests, rapid diagnostic kits, and laboratory analyzers intended for application across hospitals, clinical laboratories, blood banks, and public health screening programs.

Market dynamics include procurement by healthcare institutions, integration into routine infectious disease screening and clinical laboratory workflows, and structured sales channels ranging from direct supply agreements with hospitals and laboratories to distributor-led diagnostic equipment networks, supporting continuous testing availability across healthcare systems requiring scalable and reliable viral hepatitis detection solutions.

What's inside a VMR

industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

VMR Report Preview

Global Hepatitis B and C Diagnostics Market Drivers

The market drivers for the hepatitis B and C diagnostics market can be influenced by various factors. These may include:

Rising Global Burden of Viral Hepatitis

High global prevalence of hepatitis B and hepatitis C infections is strengthening demand for reliable diagnostic technologies across healthcare systems. According to the World Health Organization, around 296 million people were living with chronic hepatitis B infection in 2022, while approximately 58 million people were infected with chronic hepatitis C globally. Large patient populations remain undiagnosed, encouraging expansion of national screening campaigns across multiple countries. Screening initiatives targeting pregnant women, blood donors, and high risk groups are increasing diagnostic testing volumes within hospitals and clinical laboratories. Growing awareness regarding complications such as liver cirrhosis and liver cancer is encouraging earlier disease detection. Hepatitis screening panels are increasingly incorporated within routine clinical diagnostic programs.

Expansion of Government-Led Hepatitis Elimination Programs

National hepatitis elimination initiatives are accelerating diagnostic adoption across public healthcare systems worldwide. Financial resources are allocated toward mass screening programs, vaccination support, and antiviral treatment access. The World Health Organization global hepatitis strategy targets a 90% reduction in new hepatitis infections and a 65% reduction in hepatitis related deaths by 2030, encouraging countries to strengthen diagnostic capacity. Large population screening campaigns are increasing demand for automated immunoassay platforms and molecular diagnostic systems capable of processing high testing volumes. Diagnostic infrastructure expansion across developing healthcare systems is supported by international health organizations.

Increasing Adoption of Molecular Diagnostic Technologies

Rapid advancement in molecular diagnostic technologies is supporting stronger testing accuracy and earlier infection detection. Polymerase chain reaction testing enables highly sensitive identification of viral DNA or RNA, supporting early stage diagnosis and precise viral load monitoring. Automated molecular analyzers are increasingly adopted within hospitals and specialized diagnostic laboratories for treatment monitoring and therapy assessment. Higher diagnostic sensitivity supports improved physician decision making regarding disease progression and antiviral treatment effectiveness. Expansion of molecular testing capacity across clinical laboratories is strengthening long-term demand for advanced diagnostic platforms.

Growth of Point-of-Care Testing in Decentralized Healthcare Settings

Point-of-care diagnostic technologies are gaining wider utilization across rural healthcare facilities, community clinics, and outreach screening programs. Rapid diagnostic kits deliver test results within minutes without dependence on large laboratory infrastructure. Portable testing solutions are utilized by community health workers during field screening campaigns and mobile healthcare initiatives. Faster diagnosis supports quicker linkage to treatment programs and clinical follow up. Increasing focus on decentralized healthcare delivery models is strengthening demand for compact and easy to operate hepatitis diagnostic solutions.

Global Hepatitis B and C Diagnostics Market Restraints

Several factors act as restraints or challenges for the hepatitis B and C diagnostics market. These may include:

High Cost of Advanced Molecular Testing Systems

High cost of advanced molecular diagnostic platforms is restraining the hepatitis B and C diagnostics market, as procurement of automated PCR analyzers and specialized reagents requires substantial financial investment across healthcare laboratories. Budget limitations across smaller clinics and diagnostic centers reduce adoption of advanced testing technologies. Preference toward lower cost serological screening methods remains common within cost sensitive healthcare environments. Expansion of molecular testing infrastructure faces limitations across regions operating under restricted healthcare funding.

Limited Diagnostic Infrastructure in Low Income Regions

Limited diagnostic infrastructure across several low income regions is restricting wider testing coverage, as laboratory facilities remain insufficient for large scale viral hepatitis screening. Availability of trained laboratory personnel and advanced testing equipment remains uneven across rural healthcare centers. Reagent supply logistics and sample transportation challenges introduce operational disruptions within testing programs. Diagnostic service accessibility across remote communities progresses at a slower pace under constrained healthcare resources.

Social Stigma and Limited Public Awareness

Social stigma associated with viral hepatitis infection is slowing diagnostic demand, as fear of discrimination discourages voluntary testing across certain populations. Limited public awareness regarding disease transmission and treatment options reduces participation in screening initiatives. Community level misconceptions influence healthcare seeking behavior within high risk groups. Public health outreach campaigns face behavioral and cultural barriers affecting wider diagnostic adoption.

Regulatory Compliance and Quality Assurance Requirements

Strict regulatory compliance and quality assurance requirements are influencing diagnostic product commercialization, as clinical validation studies and documentation processes extend approval timelines. Diagnostic developers face extensive evaluation procedures designed to ensure testing accuracy and patient safety. Compliance with international laboratory standards increases operational and certification costs. Regulatory variation across countries complicates cross border distribution strategies for diagnostic manufacturers.

Global Hepatitis B and C Diagnostics Market Opportunities

The landscape of opportunities within the hepatitis B and C diagnostics market is driven by several growth-oriented factors and shifting global demands. These may include:

Integration of Automated Laboratory Systems

High integration of automated laboratory systems is shaping the hepatitis B and C diagnostics market, as high throughput analyzers enable processing of large screening volumes with improved accuracy, consistent performance, and reduced manual workload. Standardized workflows, automated sample handling, and faster turnaround times are supported across hospitals, clinical laboratories, and blood banks. Integrated laboratory platforms combining serology, molecular diagnostics, and laboratory information software are being increasingly deployed to streamline operations, reduce human error, and ensure reproducible results across large scale testing programs.

Expansion of Community Based Screening Programs

Increasing expansion of community based screening programs is influencing market direction, as outreach testing in high risk populations including intravenous drug users, migrants, and underserved communities is strengthened. Mobile testing clinics, temporary diagnostic stations, and field screening campaigns are driving demand for portable and rapid diagnostic solutions capable of operating in resource limited settings. Diagnostic platforms designed for ease of use, minimal training requirements, and quick result reporting are being adopted to improve accessibility, increase participation rates, and support public health initiatives targeting hepatitis elimination.

Growth of Digital Health and Laboratory Information Systems

Rising adoption of digital health tools and laboratory information systems is shaping the hepatitis B and C diagnostics market, as electronic health records and integrated lab platforms enable faster transmission of results, automated reporting, and improved patient follow up. Integration of diagnostic data with clinical decision support systems allows healthcare providers to monitor infection progression, treatment response, and outbreak trends more effectively. Implementation of cloud-based reporting, data analytics, and remote monitoring tools is enhancing operational efficiency, regulatory compliance, and overall quality of hepatitis screening and surveillance programs.

Development of Multiplex Testing Technologies

Growing development of multiplex testing technologies is impacting the hepatitis B and C diagnostics market, as diagnostic platforms capable of detecting multiple infectious diseases within a single test panel are gaining preference. Laboratories and hospitals are increasingly adopting systems that simultaneously screen hepatitis viruses alongside HIV, syphilis, and other blood-borne pathogens. Multiplex assays reduce testing time, operational costs, and sample requirements, while improving workflow efficiency for large scale screening programs. Continuous investment in assay innovation and automation supports broader infectious disease detection capabilities, enhancing public health monitoring and outbreak response efforts.

Global Hepatitis B and C Diagnostics Market Segmentation Analysis

The Global Hepatitis B and C Diagnostics Market is segmented based on Test Type, End-User, and Geography.

Hepatitis B and C Diagnostics Market, By Test Type

Immunoassays: Immunoassays dominate diagnostic adoption within hepatitis screening programs due to strong reliability and large scale laboratory compatibility. Enzyme-linked immunosorbent assays and chemiluminescent immunoassays detect viral antigens and antibodies with high sensitivity. Hospitals and blood banks widely use these technologies during routine screening and donor safety testing. Automated immunoassay analyzers support high sample throughput and consistent testing accuracy, strengthening their role within clinical laboratory workflows.

Molecular Diagnostics: Molecular diagnostics are experiencing rapid growth within hepatitis detection and monitoring activities. Polymerase chain reaction testing enables identification of viral genetic material at very early stages of infection. Physicians rely on viral load measurements to monitor treatment response and disease progression. Advanced molecular platforms provide high sensitivity and precise quantification of viral replication levels. Expansion of molecular diagnostic laboratories across hospitals and research institutions is strengthening this segment.

Rapid Diagnostic Tests: Rapid diagnostic tests are gaining increasing acceptance in decentralized healthcare environments. These portable kits provide screening results within minutes without requirement for advanced laboratory infrastructure. Community healthcare workers utilize rapid tests during outreach screening campaigns and mobile clinics. Easy operation, minimal training requirements, and lower cost make rapid diagnostic tests suitable for large-scale population testing initiatives.

Hepatitis B and C Diagnostics Market, By End-User

Hospitals: Hospitals dominate diagnostic utilization due to integrated laboratory infrastructure and high patient inflow. Hepatitis testing forms part of routine clinical evaluations, pre-surgical screening, and inpatient diagnostics. Large hospital laboratories operate automated immunoassay and molecular testing systems capable of processing high sample volumes. Specialized liver disease clinics within hospitals also rely heavily on viral load monitoring technologies.

Diagnostic Laboratories: Diagnostic laboratories maintain strong market participation due to specialized testing capability and regional sample collection networks. Reference laboratories perform complex molecular testing and confirmatory diagnostics for hospitals and clinics. Large laboratory chains operate centralized facilities with advanced automation systems that support efficient processing of large screening volumes.

Blood Banks: Blood banks maintain strict screening protocols to ensure transfusion safety. Every donated blood unit undergoes mandatory testing for hepatitis B and hepatitis C infections. Blood bank laboratories utilize highly sensitive immunoassay and nucleic acid testing technologies to detect potential viral contamination. Continuous blood donation programs sustain consistent diagnostic demand across this segment.

Point-of-Care Settings: Point-of-care environments such as community clinics, rural healthcare centers, and outreach programs are witnessing rising diagnostic activity. Rapid testing technologies allow healthcare providers to conduct screening outside conventional laboratory facilities. Early diagnosis within community settings improves patient referral for confirmatory testing and treatment services.

Hepatitis B and C Diagnostics Market, By Geography

North America: North America dominates the hepatitis B and C diagnostics market, commanding substantial market share due to advanced healthcare infrastructure, strong laboratory networks, and high diagnostic awareness. Hospitals and diagnostic laboratories are widely implementing automated immunoassay and molecular testing platforms. Government health agencies are supporting early disease detection through regular screening programs and surveillance initiatives, sustaining continuous market demand and maintaining significant market presence.

Europe: Europe leads the market share within the hepatitis B and C diagnostics market and is maintaining significant market presence, driven by well established public healthcare systems and infectious disease monitoring frameworks. National hepatitis elimination strategies are experiencing a surge in market demand, encouraging routine screening among high risk populations. Advanced laboratory infrastructure and stringent regulatory quality standards are strengthening adoption of modern diagnostic technologies across the region.

Asia Pacific: Asia Pacific is emerging as the fastest growing segment and is registering accelerated market size growth in the hepatitis B and C diagnostics market, driven by large patient populations and increasing prevalence of viral hepatitis infections. National governments across China, India, and Southeast Asian countries are expanding large scale screening initiatives. Growing healthcare investments, improving laboratory infrastructure, and rising public awareness are expanding rapidly within the regional market.

Latin America: Latin America is experiencing steady growth and maintaining moderate market presence in the hepatitis B and C diagnostics market, supported by expanding public health screening programs and improving healthcare accessibility. Community testing campaigns funded by governments and international organizations are driving higher disease detection rates. Diagnostic laboratories across major urban centers are gradually adopting automated testing technologies, contributing to regional market expansion.

Middle East and Africa: The Middle East and Africa region is maintaining gradual market expansion within the hepatitis B and C diagnostics market. Strengthening infectious disease surveillance programs and enhanced blood safety regulations are supporting adoption of modern diagnostic solutions. Expansion of diagnostic infrastructure and collaborations with international healthcare agencies are contributing to long-term improvement in testing capacity, sustaining a growing market presence across the region.

Key Players

• The competitive environment is remaining brand-driven, with established players leveraging distribution scale, product breadth, and brand trust. Competitive differentiation is shifting toward material transparency, comfort-led design, and sustainability positioning, while portfolio consolidation and brand acquisition activity are reshaping ownership dynamics.
• Key Players Operating in the Global Hepatitis B and C Diagnostics Market
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Siemens Healthineers
• Danaher Corporation
• bioMerieux SA
• Becton, Dickinson and Company
• Hologic, Inc.
• DiaSorin S.p.A.
• Sysmex Corporation
• Grifols S.A.
• Market Outlook and Strategic Implications
• Growth momentum is remaining stable, while strategic focus is increasingly prioritizing compliance readiness, premiumization, and consumer trust reinforcement. Investment allocation is shifting toward scalable innovation and lifecycle value, as transparency, safety assurance, and access expansion are emerging as long-term competitive differentiators.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 MARKET DEFINITION
• 1.2 MARKET SEGMENTATION
• 1.3 RESEARCH TIMELINES
• 1.4 ASSUMPTIONS
• 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

• 2.1 DATA MINING
• 2.2 SECONDARY RESEARCH
• 2.3 PRIMARY RESEARCH
• 2.4 SUBJECT MATTER EXPERT ADVICE
• 2.5 QUALITY CHECK
• 2.6 FINAL REVIEW
• 2.7 DATA TRIANGULATION
• 2.8 BOTTOM-UP APPROACH
• 2.9 TOP-DOWN APPROACH
• 2.10 RESEARCH FLOW
• 2.11 DATA SOURCES

3 EXECUTIVE SUMMARY

• 3.1 GLOBAL HEPATITIS B AND C DIAGNOSTICS MARKET OVERVIEW
• 3.2 GLOBAL HEPATITIS B AND C DIAGNOSTICS MARKET ESTIMATES AND FORECAST (USD BILLION)
• 3.3 GLOBAL HEPATITIS B AND C DIAGNOSTICS MARKET ECOLOGY MAPPING
• 3.4 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
• 3.5 GLOBAL HEPATITIS B AND C DIAGNOSTICS MARKET ABSOLUTE MARKET OPPORTUNITY
• 3.6 GLOBAL HEPATITIS B AND C DIAGNOSTICS MARKET ATTRACTIVENESS ANALYSIS, BY REGION
• 3.7 GLOBAL HEPATITIS B AND C DIAGNOSTICS MARKET ATTRACTIVENESS ANALYSIS, BY TEST TYPE
• 3.8 GLOBAL HEPATITIS B AND C DIAGNOSTICS MARKET ATTRACTIVENESS ANALYSIS, BY END-USER
• 3.9 GLOBAL HEPATITIS B AND C DIAGNOSTICS MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
• 3.10 GLOBAL HEPATITIS B AND C DIAGNOSTICS MARKET, BY TEST TYPE (USD BILLION)
• 3.11 GLOBAL HEPATITIS B AND C DIAGNOSTICS MARKET, BY END-USER (USD BILLION)
• 3.12 GLOBAL HEPATITIS B AND C DIAGNOSTICS MARKET, BY GEOGRAPHY (USD BILLION)
• 3.13 FUTURE MARKET OPPORTUNITIES

4 MARKET OUTLOOK

• 4.1 GLOBAL HEPATITIS B AND C DIAGNOSTICS MARKET EVOLUTION
• 4.2 GLOBAL HEPATITIS B AND C DIAGNOSTICS MARKET OUTLOOK
• 4.3 MARKET DRIVERS
• 4.4 MARKET RESTRAINTS
• 4.5 MARKET TRENDS
• 4.6 MARKET OPPORTUNITY
• 4.7 PORTER'S FIVE FORCES ANALYSIS
  • 4.7.1 THREAT OF NEW ENTRANTS
  • 4.7.2 BARGAINING POWER OF SUPPLIERS
  • 4.7.3 BARGAINING POWER OF BUYERS
  • 4.7.4 THREAT OF SUBSTITUTE USER TEST TYPES
  • 4.7.5 COMPETITIVE RIVALRY OF EXISTING COMPETITORS
• 4.8 VALUE CHAIN ANALYSIS
• 4.9 PRICING ANALYSIS
• 4.10 MACROECONOMIC ANALYSIS

5 MARKET, BY TEST TYPE

• 5.1 OVERVIEW
• 5.2 GLOBAL HEPATITIS B AND C DIAGNOSTICS MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY TEST TYPE
• 5.3 IMMUNOASSAYS
• 5.4 MOLECULAR DIAGNOSTICS
• 5.5 RAPID DIAGNOSTIC TESTS

6 MARKET, BY END-USER

• 6.1 OVERVIEW
• 6.2 GLOBAL HEPATITIS B AND C DIAGNOSTICS MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY END-USER
• 6.3 HOSPITALS
• 6.4 DIAGNOSTIC LABORATORIES
• 6.5 BLOOD BANKS
• 6.6 POINT-OF-CARE SETTINGS

7 MARKET, BY GEOGRAPHY

• 7.1 OVERVIEW
• 7.2 NORTH AMERICA
  • 7.2.1 U.S.
  • 7.2.2 CANADA
  • 7.2.3 MEXICO
• 7.3 EUROPE
  • 7.3.1 GERMANY
  • 7.3.2 U.K.
  • 7.3.3 FRANCE
  • 7.3.4 ITALY
  • 7.3.5 SPAIN
  • 7.3.6 REST OF EUROPE
• 7.4 ASIA PACIFIC
  • 7.4.1 CHINA
  • 7.4.2 JAPAN
  • 7.4.3 INDIA
  • 7.4.4 REST OF ASIA PACIFIC
• 7.5 LATIN AMERICA
  • 7.5.1 BRAZIL
  • 7.5.2 ARGENTINA
  • 7.5.3 REST OF LATIN AMERICA
• 7.6 MIDDLE EAST AND AFRICA
  • 7.6.1 UAE
  • 7.6.2 SAUDI ARABIA
  • 7.6.3 SOUTH AFRICA
  • 7.6.4 REST OF MIDDLE EAST AND AFRICA

8 COMPETITIVE LANDSCAPE

• 8.1 OVERVIEW
• 8.2 KEY DEVELOPMENT STRATEGIES
• 8.3 COMPANY REGIONAL FOOTPRINT
• 8.4 ACE MATRIX
  • 8.5.1 ACTIVE
  • 8.5.2 CUTTING EDGE
  • 8.5.3 EMERGING
  • 8.5.4 INNOVATORS

9 COMPANY PROFILES

• 9.1 OVERVIEW
• 9.2 ABBOTT LABORATORIES
• 9.3 F. HOFFMANN-LA ROCHE LTD.
• 9.4 SIEMENS HEALTHINEERS
• 9.5 DANAHER CORPORATION
• 9.6 BIOMERIEUX SA, BECTON
• 9.7 DICKINSON AND COMPANY
• 9.8 HOLOGIC, INC.
• 9.9 DIASORIN S.P.A.
• 9.10 SYSMEX CORPORATION
• 9.11 GRIFOLS S.A.